The anti-TIGIT mAb Vibostolimab (Merck) was evaluated in patients with NSCLC as monotherapy or in combination with the anti-PD-1 mAb pembrolizumab (Merck) in a phase I study (NCT02964013), showing objective response rate of 26% when combined with pembrolizumab (26). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.